NeuroOne Medical Technologies Corp
NMTC0.790USD
+0.032+4.20%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
24.79MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über NeuroOne Medical Technologies Corp Unternehmen
NeuroOne Medical Technologies Corporation is a medical technology company. It is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. It may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.
Unternehmensinformationen
BörsenkürzelNMTC
Name des UnternehmensNeuroOne Medical Technologies Corp
IPO-datumNov 09, 2012
CEOMr. David A. (Dave) Rosa
Anzahl der mitarbeiter17
WertpapierartOrdinary Share
GeschäftsjahresendeNov 09
Addresse7599 Anagram Dr
StadtEDEN PRAIRIE
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl55344-7399
Telefon19524261383
Websitehttps://nmtc1.com/
BörsenkürzelNMTC
IPO-datumNov 09, 2012
CEOMr. David A. (Dave) Rosa
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. David A. (Dave) Rosa
Mr. David A. (Dave) Rosa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
618.21K
-0.40%
Mr. Mark Christianson
Mr. Mark Christianson
Co-Founder, Business Development Director, Medical Sales Liaison
Co-Founder, Business Development Director, Medical Sales Liaison
261.24K
-3.78%
Mr. Paul Buckman
Mr. Paul Buckman
Independent Chairman of the Board
Independent Chairman of the Board
136.80K
+25.48%
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Independent Director
Independent Director
114.41K
+32.06%
Mr. Steve Mertens
Mr. Steve Mertens
Chief Technology Officer
Chief Technology Officer
102.66K
-0.87%
Mr. Edward (Ed) Andrle
Mr. Edward (Ed) Andrle
Independent Director
Independent Director
92.00K
+43.25%
Mr. Chris Donovan
Mr. Chris Donovan
Investor Relations
Investor Relations
--
--
Ms. Emily Johns
Ms. Emily Johns
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Mr. Ronald (Ron) Mcclurg
Mr. Ronald (Ron) Mcclurg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Christopher R. Volker
Mr. Christopher R. Volker
Chief Operating Officer
Chief Operating Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. David A. (Dave) Rosa
Mr. David A. (Dave) Rosa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
618.21K
-0.40%
Mr. Mark Christianson
Mr. Mark Christianson
Co-Founder, Business Development Director, Medical Sales Liaison
Co-Founder, Business Development Director, Medical Sales Liaison
261.24K
-3.78%
Mr. Paul Buckman
Mr. Paul Buckman
Independent Chairman of the Board
Independent Chairman of the Board
136.80K
+25.48%
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Independent Director
Independent Director
114.41K
+32.06%
Mr. Steve Mertens
Mr. Steve Mertens
Chief Technology Officer
Chief Technology Officer
102.66K
-0.87%
Mr. Edward (Ed) Andrle
Mr. Edward (Ed) Andrle
Independent Director
Independent Director
92.00K
+43.25%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Merchant Adventure Fund LP
8.43%
Manchester Management Company, L.L.C.
4.75%
AWM Investment Company, Inc.
2.34%
The Vanguard Group, Inc.
2.23%
Rosa (David A)
1.24%
Other
81.01%
Aktionäre
Aktionäre
Anteil
Merchant Adventure Fund LP
8.43%
Manchester Management Company, L.L.C.
4.75%
AWM Investment Company, Inc.
2.34%
The Vanguard Group, Inc.
2.23%
Rosa (David A)
1.24%
Other
81.01%
Aktionärstypen
Aktionäre
Anteil
Corporation
8.43%
Hedge Fund
4.77%
Individual Investor
4.25%
Investment Advisor/Hedge Fund
3.35%
Investment Advisor
2.53%
Research Firm
0.31%
Other
76.36%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
52
11.78M
23.64%
+1.19M
2025Q1
54
11.51M
24.26%
+968.46K
2024Q4
55
12.46M
40.67%
+1.38M
2024Q3
55
11.22M
39.84%
+2.23M
2024Q2
51
10.72M
41.07%
+2.35M
2024Q1
52
11.45M
45.01%
+2.75M
2023Q4
57
9.37M
38.68%
+871.77K
2023Q3
54
7.90M
33.50%
+2.01M
2023Q2
48
4.40M
25.73%
-1.65M
2023Q1
47
4.27M
25.69%
-1.26M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Merchant Adventure Fund LP
4.20M
8.43%
+2.95M
+236.00%
Dec 31, 2024
Manchester Management Company, L.L.C.
2.36M
4.75%
+864.05K
+57.60%
Jan 03, 2025
AWM Investment Company, Inc.
1.17M
2.34%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.11M
2.23%
+191.16K
+20.79%
Mar 31, 2025
Rosa (David A)
618.21K
1.24%
-2.46K
-0.40%
Jun 30, 2025
McClurg (Ronald W.)
353.20K
0.71%
+200.00K
+130.54%
Apr 04, 2025
Geode Capital Management, L.L.C.
345.98K
0.69%
+34.32K
+11.01%
Mar 31, 2025
Christianson (Mark)
261.24K
0.52%
-10.25K
-3.78%
Jun 30, 2025
Lytton (Laurence W)
208.33K
0.42%
-1.64M
-88.75%
Mar 31, 2025
Buckman (Paul R)
136.80K
0.27%
+27.78K
+25.48%
Feb 14, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
